Podcast | AANEM 2025: Conference Review and Analysis for New Data on Emerging BAFF/APRIL Inhibitors for the Management of Patients with Generalized Myasthenia Gravis

Course Title for Certificate

Name

First NameLast Name

Email

example@example.com

What best describes your title?

If PharmD, DOB

Date

If PharmD, NABP ID#:

1. What is the scientific rationale of the reported efficacy for telitacicept when controlled trials with the two other similar B cell trophic factors, atacicept and belimumab, and one anti-B cell agent, rituximab, were ineffective in generalized myasthenia gravis (gMG)?

2. That rationale for performing a trial with telitacicept in gMG is that:

3. The primary endpoint in the recent phase 3, double blinded, placebo controlled telitacicept myasthenia gravis trial was:

4. A significant observation in the recent phase 3, double blinded, placebo controlled telitacicept myasthenia gravis trial was:

How many patients do you currently see each year with myasthenia gravis?

How many years have you been in practice?

Learning Objectives

Rows	Poor	Fair	Good	Very Good	Excellent
Analyze relevant new data on BAFF/APRIL inhibitors discussed at AANEM 2025 for the most up-to-date information on emerging treatment approaches to gMG
Evaluate the potential role of emerging BAFF/APRIL inhibitor therapies to manage and improve outcomes in patients with gMG

Please provide us with feedback regarding your experience at the activity:

Rows	Poor	Fair	Good	Very Good	Excellent
Overall
Content
Usefulness

Do you feel this activity was fair, balanced, and free of commercial bias?

If no, please explain:

This educational activity will result in a change in my role as a healthcare team member.

Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:

What factors beyond clinical care that effect the health of your patients does your team experience?

Attestation:

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM .

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour, including 1.0 Pharmacotherapeutic Contact Hour (Provider #P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEUs) of Continuing Pharmacy Education Credit (JA4008190-0000-25-034-H01-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Date

Credits